Wednesday, September 19, 2018
Valeo Pharma Inc., a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products, and Besins Healthcare, a global pharmaceutical company world leader in novel therapies for gynecology and andrology, today announced a strategic agreement to commercialize Utrogestan® (micronised natural progesterone; 200mg vaginal capsules) in Canada. Utrogestan is indicated for luteal phase support during in-vitro fertilization (IVF) cycles.
Under the terms of the agreement with Besins Healthcare, Valeo Pharma is responsible for all aspects of sales, marketing, quality and distribution activities pertaining to Utrogestan® 200mg vaginal capsules in Canada.
"Besins Healthcare has an international track record of successfully developing, partnering and commercializing Specialty Woman's Health Products," said Steve Saviuk, Chief Executive Officer of Valeo Pharma. "We are excited to add this unique strength of micronized progesterone (Utrogestan® 200mg vaginal capsules) to our Specialty Pharmaceutical portfolio and offer a new choice in a growing area of concern for Canadian families."
"As Utrogestan® has already been granted marketing approval by Health Canada, we are on track for a 2019 product launch," added Marc Leger, Chief Commercial Officer. "Our Specialty pipeline continues to build and we project to launch several new products in Canada over the next 12-18 months."
Antoine Besins, CEO of Besins Healthcare said "We are pleased that Utrogestan is being made available to meet patients' needs in Canada, as in over a hundred countries around the world".
Sunil Sehgal, President, Ascend Therapeutics LLC, a Besins Healthcare company operating in the U.S.A., expressed, "we welcome the opportunity to work closely with Valeo Pharma and look forward to collaborating for a successful launch of Utrogestan in early 2019".
